BioConvergence for Health (BioConvS) is a "Major Domain of Research and Innovation" (DIM) initiative by the Île-de-France Region, aimed at structuring the communities of synthetic biology, biotherapy, and bioproduction to support the transition from scientific excellence to innovation and position Île-de-France as an international reference in the field.

BioConvS is led by Université Paris Cité in partnership with Sorbonne Université, Institut Curie - PSL, Institut Micalis (INRAe, AgroParisTech, Université Paris Saclay), INSERM, Généthon, Génopole, and other partners. BioConvS brings together stakeholders from both public and private sectors and benefits from a maximum support of €12.5M from the Île-de-France Region for the 2022-2026 labeling period. More details about DIM BioConvS are available at: https://bioconvs.org/.

This call will fund four doctoral scholarships for projects related to one of the DIM BioConvS themes:

• Engineering life sciences and bioproduction
• Development of therapeutic proof-of-concepts
• New high-throughput and standardized analytical methods
• Digital tools or AI to enhance data analysis or modeling in quality control and production methods
• Ensuring inclusive, responsible, and sustainable BioConvergence

Open period: January 20 – April 30, 2025.

Only doctoral theses supervised by at least two teams (the second team may be a company) located in Île-de-France are eligible. Additional teams may participate in the project to provide specific complementary expertise without geographical limitation. Teams outside Île-de-France will not receive funding.

Startups and companies from Île-de-France may be associated with the project but will not receive funding through this call. The participation of a company will be an asset.

Language requirements: Proposals must be written in English, with a summary in French.

BioconvS website

Join our LinkedIn group

Follow our LinkedIn page

Discover our funded projects

Les DIM de la Région Ile-de-France

Qu'est-ce que c'est un DIM?